This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
The goal of this activity is to discuss the latest approaches to the treatment of older patients with MDS and AML.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this enduring material for a maximum of 2.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 5/21/2013; Reviewed and Renewed: 9/23/2014
Valid for credit through: 9/23/2015, 11:59 PM EST
processing....
AA = aplastic anemia
ALL = acute lymphoblastic leukemia
ALLIANCE trial = Alliance for Clinical Trials in Oncology
AML = acute myeloid leukemia
ASH = American Society of Hematology
ATG = antithymocyte globulin
ATRA = all-trans-retinoic acid
CALGB = Cancer and Leukemia Group B
CBF = core-binding factor
CEBPA = CCAAT/enhancer binding protein-alpha
CIBMTR = Center for International Blood and Marrow Transplant Research
CMML = chronic myelomonocytic leukemia
CR = complete remission
CRBN = cereblon
DA = daunorubicin + cytarabine
DACi = deacetylase activity inhibitor
AGO = daunorubicin + cytarabine + gemtuzumab
DNMT3A = DNA methyltransferase 3A
DNR = daunorubicin
DFS = disease-free survival
ECOG = European Cooperative Oncology Group
EFS = event-free survival
ESA = erythropoiesis-stimulating agent
FDA = US Food and Drug Administration
G-CSF = granulocyte-colony stimulating factor
FHCRC = Fred Hutchinson Cancer Research Center
FLT3 = FMS-like tyrosine kinase 3
GVHD = graft-versus-host disease
HCT = hematopoietic cell transplantation
HCT-CI = hematopoietic cell transplantation comorbidity index
HLA = human leukocyte antigen
HMA = hypomethylating agent
IL-3 = interleukin 3
IMiDs = immunomodulatory derivatives
IPSS = International Prognostic Scoring System
JAK-2 = Janus tyrosine kinase 2
JCO = Journal of Clinical Oncology
LD = low-dose
LDAC = low-dose cytosine arabinoside (Ara-C)
LGL = large granular lymphocyte
MAP kinase = mitogen-activated protein kinase
MCV = mean corpuscular volume
MDA = MD Anderson Cancer Center
MDACC = MD Anderson Cancer Cancer
MDS = myelodysplastic syndromes
MPD = myeloproliferative disease
MRC = Medical Research Council
MRD = minimal residual disease
NCCN = National Comprehensive Cancer Network
NIH = National Institutes of Health
NK cells = natural killer cells
NMDP = National Marrow Donor Program®
ORR = overall response rate
OS = overall survival
PRCA = pure red cell aplasia
RARS = refractory anemia with ring sideroblasts
RBC = red blood cell
RFS = relapse-free survival
RIC = reduced-intensity conditioning (regimen)
SC = supportive care
SWOG = formerly the Southwest Oncology Group
TET2 = Ten-Eleven-Translocation-2
TNFα = tumor necrosis factor alpha
TRM = transplant-related mortality (risk score)
VEGF = vascular endothelial growth factor
WBC = white blood cell count
WHO = World Health Organization
WPSS = WHO classification-based Prognostic Scoring System
« Return to: Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients |